TW200519094A - Pyrimidines useful as modulators of voltage-gated ion channels - Google Patents
Pyrimidines useful as modulators of voltage-gated ion channelsInfo
- Publication number
- TW200519094A TW200519094A TW093120064A TW93120064A TW200519094A TW 200519094 A TW200519094 A TW 200519094A TW 093120064 A TW093120064 A TW 093120064A TW 93120064 A TW93120064 A TW 93120064A TW 200519094 A TW200519094 A TW 200519094A
- Authority
- TW
- Taiwan
- Prior art keywords
- voltage
- modulators
- ion channels
- gated ion
- pyrimidines useful
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48436203P | 2003-07-02 | 2003-07-02 | |
| US50020003P | 2003-09-04 | 2003-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200519094A true TW200519094A (en) | 2005-06-16 |
Family
ID=33567720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093120064A TW200519094A (en) | 2003-07-02 | 2004-07-02 | Pyrimidines useful as modulators of voltage-gated ion channels |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7816529B2 (https=) |
| EP (1) | EP1638955A2 (https=) |
| JP (1) | JP2007521287A (https=) |
| KR (1) | KR20060032190A (https=) |
| AR (1) | AR045010A1 (https=) |
| AU (1) | AU2004253962A1 (https=) |
| CA (1) | CA2531061A1 (https=) |
| IL (1) | IL172937A0 (https=) |
| MX (1) | MXPA06000051A (https=) |
| NO (1) | NO20060518L (https=) |
| PE (1) | PE20051029A1 (https=) |
| RU (1) | RU2006102955A (https=) |
| TW (1) | TW200519094A (https=) |
| WO (1) | WO2005003099A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638955A2 (en) * | 2003-07-02 | 2006-03-29 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| EP1863796A1 (en) * | 2005-03-22 | 2007-12-12 | NeuroSearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
| US7858786B2 (en) * | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
| EP1877381A1 (en) * | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyridines useful as modulators of ion channels |
| WO2006130493A2 (en) * | 2005-05-31 | 2006-12-07 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
| WO2007125331A2 (en) | 2006-04-26 | 2007-11-08 | Cancer Research Technology Limited | Amino-ethyl-amino-aryl (aeaa) compounds and their use |
| EP2043654A2 (en) * | 2006-06-12 | 2009-04-08 | Vertex Pharmaceuticals, Inc. | Thienopyrimidines useful as modulators of ion channels |
| JP2010519328A (ja) | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 |
| WO2008110891A2 (en) * | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| PE20090305A1 (es) | 2007-05-22 | 2009-03-15 | Wyeth Corp | Proceso mejorado para la elaboracion de hidrazidas |
| JP2009007273A (ja) * | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | ジアミノピリミジン化合物の製造方法 |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| JP5372943B2 (ja) * | 2007-10-11 | 2013-12-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびそれらの使用 |
| DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
| EP2240025A4 (en) * | 2008-01-30 | 2012-03-28 | Glaxosmithkline Llc | NEW SEE INHIBITORS AND THEIR USE |
| WO2009097476A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| WO2009097474A1 (en) * | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| US20090198057A1 (en) * | 2008-02-05 | 2009-08-06 | Pu-Ping Lu | Certain Chemical Entities, Compositions, and Methods |
| US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| AR075196A1 (es) | 2009-02-03 | 2011-03-16 | Otsuka Pharma Co Ltd | Un derivado de cianopirimidina para el tratamiento de una enfermedad ocular |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| CN103221408A (zh) * | 2010-09-13 | 2013-07-24 | 诺瓦提斯公司 | 三嗪-*二唑类化合物 |
| JP6116554B2 (ja) * | 2011-07-07 | 2017-04-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | がんの処置のための置換されたアザ複素環 |
| ES2730112T3 (es) | 2015-03-09 | 2019-11-08 | Bristol Myers Squibb Co | Lactamas como inhibidores de ROCK |
| GB201721751D0 (en) * | 2017-12-22 | 2018-02-07 | Adorx Therapeutics Ltd | Compounds |
| EP4320103A1 (en) * | 2021-04-09 | 2024-02-14 | Quanta Therapeutics, Inc. | Pyrimidine based ras modulators and uses thereof |
| EP4452253A4 (en) * | 2021-12-23 | 2026-04-15 | The Katholieke Univ Leuven | 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD |
| AU2023218370B2 (en) | 2022-02-09 | 2024-11-28 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| IL317601A (en) | 2022-05-25 | 2025-02-01 | Quanta Therapeutics Inc | Pyrimidine-based modulators and their uses |
| WO2024192424A1 (en) | 2023-03-15 | 2024-09-19 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB901749A (en) | 1957-12-06 | 1962-07-25 | Ciba Ltd | New 2-substituted pyrimidines |
| US3040047A (en) * | 1960-04-04 | 1962-06-19 | Takeda Pharmaceutical | 2-(pyrazol-1-yl)-pyrimidine derivatives |
| US3850928A (en) * | 1969-11-04 | 1974-11-26 | American Home Prod | Substituted 6-alkylamino-2-phenyl-5-pyrimidine carboxylic acids |
| US3850931A (en) * | 1971-06-25 | 1974-11-26 | American Home Prod | 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters |
| US3759922A (en) * | 1971-06-25 | 1973-09-18 | American Home Prod | Preparation of pyrimido(5,4-c)(1,5) benz oxazepin-5(11h)-ones and intermediates |
| US3860596A (en) * | 1972-08-31 | 1975-01-14 | American Home Prod | 2-aryl-4-substituted-amino-5-pyrimidyl derivatives |
| DE2341925A1 (de) * | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| FR2263750A1 (en) | 1974-03-12 | 1975-10-10 | Delalande Sa | N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc. |
| FR2281117A2 (fr) * | 1974-08-09 | 1976-03-05 | Ugine Kuhlmann | Nouvelles piperazino-pyrimidines utilisables comme medicaments |
| JPS6044303B2 (ja) * | 1975-02-25 | 1985-10-02 | 大日本製薬株式会社 | ２−環状アミノ−４−アミノピリミジン誘導体の製造法 |
| EP0257102B1 (en) | 1986-02-24 | 1997-11-19 | Mitsui Petrochemical Industries, Ltd. | Agents for treating neurophathy |
| US20020183335A1 (en) * | 2001-02-20 | 2002-12-05 | Piyasena Hewawasam | 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators |
| EP1511738A4 (en) * | 2002-05-17 | 2007-05-09 | Scios Inc | TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS |
| EP1638955A2 (en) * | 2003-07-02 | 2006-03-29 | Vertex Pharmaceuticals Incorporated | Pyrimidines useful as modulators of voltage-gated ion channels |
| US7858786B2 (en) * | 2005-05-04 | 2010-12-28 | Vertex Pharmaceuticals Incoropated | Pyrimidines and pyrazines useful as modulators of ion channels |
-
2004
- 2004-07-02 EP EP04777512A patent/EP1638955A2/en not_active Withdrawn
- 2004-07-02 JP JP2006517847A patent/JP2007521287A/ja not_active Withdrawn
- 2004-07-02 PE PE20050002102004000638A patent/PE20051029A1/es not_active Application Discontinuation
- 2004-07-02 KR KR1020067000095A patent/KR20060032190A/ko not_active Ceased
- 2004-07-02 AU AU2004253962A patent/AU2004253962A1/en not_active Abandoned
- 2004-07-02 RU RU2006102955/04A patent/RU2006102955A/ru not_active Application Discontinuation
- 2004-07-02 TW TW093120064A patent/TW200519094A/zh unknown
- 2004-07-02 US US10/884,865 patent/US7816529B2/en not_active Expired - Fee Related
- 2004-07-02 WO PCT/US2004/021440 patent/WO2005003099A2/en not_active Ceased
- 2004-07-02 MX MXPA06000051A patent/MXPA06000051A/es unknown
- 2004-07-02 CA CA002531061A patent/CA2531061A1/en not_active Abandoned
- 2004-07-02 AR ARP040102352A patent/AR045010A1/es unknown
-
2006
- 2006-01-02 IL IL172937A patent/IL172937A0/en unknown
- 2006-02-01 NO NO20060518A patent/NO20060518L/no not_active Application Discontinuation
-
2010
- 2010-09-08 US US12/877,793 patent/US8324220B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005003099A2 (en) | 2005-01-13 |
| NO20060518L (no) | 2006-03-07 |
| CA2531061A1 (en) | 2005-01-13 |
| AR045010A1 (es) | 2005-10-12 |
| US20110003814A1 (en) | 2011-01-06 |
| IL172937A0 (en) | 2006-06-11 |
| JP2007521287A (ja) | 2007-08-02 |
| AU2004253962A1 (en) | 2005-01-13 |
| WO2005003099A3 (en) | 2005-05-12 |
| KR20060032190A (ko) | 2006-04-14 |
| MXPA06000051A (es) | 2006-03-21 |
| PE20051029A1 (es) | 2005-12-07 |
| EP1638955A2 (en) | 2006-03-29 |
| RU2006102955A (ru) | 2007-08-20 |
| US8324220B2 (en) | 2012-12-04 |
| US7816529B2 (en) | 2010-10-19 |
| US20050049247A1 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200519094A (en) | Pyrimidines useful as modulators of voltage-gated ion channels | |
| ZA200702375B (en) | Quinazolines useful as modulators of ion channels | |
| IL187382A0 (en) | Bicyclic derivatives as modulators of ion channels | |
| NO20054546L (no) | Kinazoliner anvendelige som modulatorer av ionekanaler | |
| TW200740803A (en) | Heterocyclic derivatives as modulators of ion channels | |
| MX2010003864A (es) | Amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| MXPA05005223A (es) | Diaminotriazoles utiles como inhibidores de proteinas cinasas. | |
| AU2004263179A8 (en) | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain | |
| MX2010003866A (es) | Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
| MX2010003865A (es) | Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje. | |
| MXPA06001494A (es) | Compuestos de piramidina condensados como inhibidores de canales ionicos gatillados por tension. | |
| NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
| AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
| AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
| AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
| WO2004108133A3 (en) | Modulators of vr1 receptor | |
| TW200514776A (en) | Aminotriazole compounds useful as inhibitors of protein kinases | |
| TW200602052A (en) | Azaindoles useful as inhibitors of JAK and other protein kinases | |
| MY158162A (en) | 5-membered heterocycle-based p38 kinase inhibitors | |
| MX2010003009A (es) | Piridil sulfonamidas como moduladores de canales ionicos. | |
| WO2006050476A3 (en) | Pyrimidine derivatives as ion channel modulators and methods of use | |
| TW200630090A (en) | Triazoles useful as inhibitors of protein kinases | |
| ZA201003352B (en) | Heterocyclic derivatives as modulators of ion channels | |
| WO2007058989A3 (en) | Quinazolines useful as modulators of voltage gated ion channels |